Euretina 2026 at a glance
At EURETINA 2026, retinal competition is increasingly shifting beyond efficacy toward treatment durability, precision medicine, new delivery approaches and AI-supported clinical decision-making.
📅 Build your schedule around the topics that matter most.
📥 Download the EURETINA 2026_Preview_by_LucidQuest
Key Retinal Therapy Trends to Watch at EURETINA 2026
Durability in nAMD: EYP-1901, Aflibercept 8 mg and Faricimab
EYP-1901, aflibercept 8 mg, faricimab and gene-therapy approaches will put extended dosing intervals and reduced treatment burden in focus.
Retinal Gene Therapy Expansion Across nAMD, DME and Inherited Disease
4D-150, Ixo-vec and emerging gene-therapy platforms will extend the discussion across neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and inherited retinal disease.
Geographic Atrophy Treatments Beyond Complement Inhibition
Vision restoration, neuroprotection, regenerative medicine and device-based approaches may broaden the geographic atrophy treatment paradigm beyond slowing disease progression.
Precision Phenotyping and AI-Supported Retinal Care
Multimodal imaging, biomarkers and AI-supported phenotyping could increasingly inform patient selection, progression risk and treatment decisions.
Competitor and Industry Signals at EURETINA 2026
4D Molecular Therapeutics: 4D-150 Clinical Development
PRISM, 4FRONT and SPECTRA data are set to build the evidence base for intravitreal 4D-150 across nAMD and DME.
Roche and Bayer: Faricimab and Eylea 8 mg Retinal Treatment Durability
Faricimab and aflibercept 8 mg will keep durability, real-world evidence and treatment optimisation central to retinal competition.
Emerging Retinal Therapy Pipeline
APL-3007, vonaprument, sonpiretigene isteparvovec, PST-611-CT1, sura-vec, SAR402663, LX102 and TTX-381 expand the emerging pipeline.
Artificial Intelligence and Machine Learning at Euretina Innovation Spotlight (EIS) 2026
AI for Clinical Decision Support
AI is set to move beyond image interpretation into risk prediction, monitoring, treatment planning and patient-centred management.
Generative AI in Vitreoretinal Clinical and Surgical Workflows
Dedicated LLM sessions suggest growing interest in integrating generative AI into vitreoretinal clinical and surgical workflows.
What We Are Watching After EURETINA 2026
- Whether durable therapies and retinal gene therapy can reduce treatment burden while maintaining consistent clinical control.
- Whether AI-derived phenotyping moves from analytical validation toward routine treatment decision support.
- Whether functional vision restoration becomes a more established development direction in geographic atrophy.
Download the EURETINA 2026 Preview Report
Download LucidQuest’s preview report for deeper analysis of the retinal therapy developments and competitive signals to watch.
📅 Build your schedule around the sessions that matter most.
📥 Download the EURETINA 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
